A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (STERIMGLI)

  • End date
    Dec 5, 2024
  • participants needed
  • sponsor
    Institut Claudius Regaud
Updated on 5 April 2022
platelet count
measurable disease
karnofsky performance status
neutrophil count
recurrent disease
malignant glioma
recurrent glioblastoma
contrast-enhanced magnetic resonance imaging
vascular endothelial growth factor
combined modality therapy


This study is a phase I/II, national, multicenter, open-label study starting with a Phase I part followed by a Phase II part.

The phase I part of the study aims to evaluate the safety of the association of hypofractionated stereotactic radiation therapy (hFSRT) and the anti-PD-L1 Durvalumab immunotherapy in patients with recurrent glioblastoma. A maximum number of 12 patients will be enrolled in this phase I part.

Once the recommended combination schema will be declared, patients will be enrolled in the Phase II part of the study in order to evaluate the efficacy (overall survival) of the combined treatment in recurrent glioblastoma. In this Phase II part, 100 patients will be assigned by randomization to one of the two following arms:

  • Arm A (control arm): Radiation therapy alone
  • Arm B (Experimental arm): Combined treatment with Anti-PD-L1 Durvalumab

Condition Glioblastoma
Treatment durvalumab, Hypofractionated stereotactic radiation therapy
Clinical Study IdentifierNCT02866747
SponsorInstitut Claudius Regaud
Last Modified on5 April 2022


Yes No Not Sure

Inclusion Criteria

Age ≥ 18 years at time of study entry
Previous histopathologic confirmation of glioblastoma
Any line of recurrence of glioblastoma proven by contrast enhanced MRI within 28 days prior to the first fraction of RT, per modified RANO criteria (Wen et al JCO 2010)
Note: Recurrence is defined as progression following therapy (i.e
chemotherapy, radiation, second surgery)
Recurrent nodule of an histologically confirmed diagnosis of World Health Organization (WHO) Grade IV malignant glioma (Glioblastoma) occurring in or out the previous irradiation fields
Recurrent disease documented by MRI evidence with a size of the recurrence evaluated on T1 post-gadolinium sequence ≤35mm
Patient for which a re-irradiation (by hFSRT) has been decided by the multidisciplinary medical board
Patients with measurable disease
Prior radiotherapy must be ended at least 12 weeks before the first fraction of RT (unless progressive disease outside of the radiation field or histopathologic confirmation of unequivocal tumor to eliminate pseudoprogression images according to RANO recommendations, Wen et al JCO 2010)
In case of previous anti-VEGF/VEGFR targeted therapy: at least 28 days between the last injection of anti-VEGF/VEGFR targeted therapy and the first fraction of RT
Karnofsky performance status ≥70
Adequate hematologic, renal and hepatic function, as defined below
Absolute Neutrophil Count ≥ 1500/mm3
Haemoglobin ≥ 9.0 g/dL
Platelet count ≥ 100,000/mm3
Total bilirubin ≤ 1.5 x ULN (for patient with confirmed Gilbert's syndrome
Total bilirubin ≤ 3 x ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN
Creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min, using the Cockcroft-Gault formula
Female CrCl = (140 - age in years) x weight in kg x 0.85 /72 x serum creatinine in mg/dL
Male CrCl = (140 - age in years) x weight in kg x 1.00/72 x serum creatinine in mg/dL
Female Patients must either be of non-reproductive potential (i.e., post-menopausal by
history: ≥60 years old and no menses for ≥ 1 year without an alternative
medical cause; OR history of hysterectomy, OR history of bilateral tubal
ligation, OR history of bilateral oophorectomy) or must have a negative serum
pregnancy test upon study entry
Written informed consent and any locally required authorization (e.g., Social security for France (Health Insurance)) obtained from the patient prior performing any protocol-related procedures, including screening evaluations
Patient willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up

Exclusion Criteria

Multifocal GBM recurrence (exception: multisite nodular recurrence (maximum: 2 sites) that can be irradiated by hFSRT according to investigator's judgement)
Prior re-irradiation (except if fulfilling the following requirements: ended at least 6 months before the first fraction of RT in the study, localized outside the target of interest for the trial, and previously re-irradiated lesion controlled at the time of study entry)
Distance between tumor and optic ways including chiasma or brainstem <1 cm
Prior exposure to Durvalumab or other anti-PD-1, anti-PD-L1, anti-CTLA4 antibodies
Patient who received a live vaccine within 30 days prior to the first fraction of RT
Current or prior use of immunosuppressive medication within 10 days before the first fraction of RT (exception: systemic corticosteroids at physiologic doses not exceeding 10 mg/day of prednisone or equivalent are allowed as well as steroids as premedication for hypersensitivity reactions (eg, CT scan premedication) - Topical, inhaled, nasal and ophthalmic steroids are not prohibited)
Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) within 28 days prior to the first fraction of RT
Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia's Correction
Active suspected or prior documented autoimmune disease (including inflammatory bowel disease, celiac disease, Wegener's granulomatosis and Hashimoto's thyroiditis)
Presence of diffuse leptomeningeal disease or extracranial disease
Note: participants with vitiligo, type I diabetes mellitus, residual
hypothyroidism due to autoimmune condition only requiring hormone replacement
psoriasis not requiring systemic treatment, or conditions not expected to
Known primary immunodeficiency or active HIV
recur in the absence of an external trigger, are permitted to enroll
Known active or chronic viral hepatitis or history of any type of hepatitis within the last 6 months indicated by positive test for hepatitis B surface antigen (HBV sAG) or hepatitis C virus antibody
History of organ transplant requiring use of immunosuppressive medication
History of active tuberculosis
Current pneumonitis or interstitial lung disease
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses
Other invasive malignancy within 2 years prior to entry into the study, except for those treated with surgical therapy only
History of severe allergic reactions to any unknown allergens or any components of the study drug
Any prior Grade ≥ 3 immune-related adverse event (irAE) or any prior corticosteroid-refractory irAE
Participation in any other clinical trial involving another investigational product within 4 weeks prior to the first fraction of RT
Participation in any other clinical trial which delivered a dose >60 Gy for the primo-treatment for glioblastoma
Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing highly effective method of birth control
Any condition that, in the clinical judgment of the investigator, is likely to prevent the patient from complying with any aspect of the protocol or that may put the patient at unacceptable risk
Mental impairment (psychiatric illness/social situations) that may compromise the ability of the patient to give informed consent and comply with the requirements of the study
Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note